Search clinical trials for: HS-10241 Almonertinib

Total 257 results

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10353 in Adult Participants With Major Depressive Disorder

Major Depressive Disorder (MDD)
Hansoh BioMedical R&D Company

Recruiting

Study of HS-10384 in Participants of Chinese Postmenopausal Women

Vasomotor Symptoms

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight and Obesity

China
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in Healthy Participants

Type 2 Diabetes

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Cystic Fibrosis

United States
Heat Biologics

Completed

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Advanced Solid Tumor

United States
Suzhou Zanrong Pharma Limited

Recruiting

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors | HER2-positive Breast Cancer

China
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostatic Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Herbert Lyerly

Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Solid Tumor

United States
HeadSense Medical
Rigshospitalet, Denmark

Unknown

Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement

Intracranial Hypertension

Denmark, Germany, Netherlands
HeadSense Medical
State Medical Center, Republic of Armenia

Completed

An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care

Stroke

Armenia
Shanghai Hansoh Biomedical Co., Ltd

Recruiting

A Study of HS-20089 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Institute of Medicinal Molecular Design, Inc.

Unknown

IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Sarcoma | Osteosarcoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Advanced Non-Small-Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10342 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Universitätsmedizin Mannheim

Withdrawn

HS-PCI in Locally Advanced Adenocarcinoma of the Lung (HIPPO-S)

Adenocarcinoma | Lung Cancer | Lymphatic Metastasis
HeadSense Medical
Oslo University Hospital

Completed

Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device

Brain Injuries | Intracranial Hypertension

Norway
Suzhou Zanrong Pharma Limited

Recruiting

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors | HER2-positive Breast Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

Healthy

China
Hansoh BioMedical R&D Company

Not yet recruiting

Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Advanced Solid Tumor
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Head and Neck Squamous Cell Carcinoma

China
Hansoh BioMedical R&D Company

Recruiting

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Metastasis Castration Resistant Prostate Cancer(mCRPC)

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Advanced or Metastatic NSCLC

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Nonsmall Cell Lung Cancer

United States
HeadSense Medical
University of Maryland, College Park

Unknown

An Evaluation of Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm

Subarachnoid Hemorrhage | Vasospasm, Intracranial

United States
HeadSense Medical

Suspended

An Evaluation of Non-Invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an Intraparenchymal Pressure Monitoring Device

Stroke | Brain Injuries | Brain Neoplasms | Intracranial Hypertension | Hydrocephalus

Japan
HeadSense Medical
Elisabeth-TweeSteden Ziekenhuis

Completed

Prospective Evaluation of the Non-invasive ICP HeadSense Monitor in TBI Patients Undergoing Invasive ICP Monitoring

Brain Injuries | Intracranial Hypertension

Netherlands
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

China
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10380 in Chinese Participants

Schizophrenia

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

Chronic HBV Infection

China
HeadSense Medical
Akron Children's Hospital

Unknown

Indirect Intracranial Pressure Measurement in Patients With Suspected or Documented Concussion

Brain Injuries | Brain Concussion

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers

Healthy
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic Phase | CML, Accelerated Phase

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand
Oslo University Hospital
University of Oslo

Completed

One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome (OUT-ACS)

Acute Coronary Syndrome | Angina, Unstable | NSTEMI - Non-ST Segment Elevation MI | Non-ST Elevation Myocardial Infarction

Norway
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder

Insomnia Disorder

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.

Healthy
HeadSense Medical
University Medical Center Goettingen; Klinikum Darmstadt; Klinikum Stuttgart

Unknown

An Evaluation of a Non-invasive Brain Monitor

Brain Injuries | Brain Neoplasms | Subarachnoid Hemorrhage | Vasospasm, Intracranial | Hydrocephalus

Germany

Search clinical trials for: HS-10241 Almonertinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations